The Rise of Decentralized Clinical Trials: 10 Companies Pushing the Field Forward

The biotech industry has been witnessing a paradigm shift in recent years as it moves away from traditional clinical trials towards a decentralized model. Decentralized clinical trials (DCTs) leverage digital technology to streamline the process, allowing for greater flexibility, reduced costs, and improved patient outcomes. This article will explore the factors driving this transition, discuss the pros and cons of DCTs, and highlight some key examples of companies and drug candidates that have successfully adopted this innovative approach.

#advertisement

The Shift to Decentralized Clinical Trials

As the FDA increasingly embraces DCTs, the industry is responding by exploring new ways to conduct clinical research. Decentralized clinical trials companies are leveraging technology such as telemedicine, mobile apps, and wearables to facilitate remote data collection and monitoring. This shift is driven by the need to improve trial efficiency, reduce costs, and enhance patient accessibility.

Pros of Decentralized Clinical Trials

1. Improved patient access and diversity: DCTs allow patients from various geographic locations and backgrounds to participate, leading to more representative and inclusive trials.
2. Reduced burden on patients: Patients can participate from the comfort of their own homes, eliminating the need for frequent travel to clinical trial sites.
3. Faster enrollment and retention: The convenience and flexibility of DCTs can lead to faster patient recruitment and reduced dropout rates.
4. Real-time data collection: Continuous monitoring through digital devices enables real-time data collection and analysis, improving the overall quality of data.

Cons of Decentralized Clinical Trials

1. Data security and privacy concerns: Protecting sensitive patient information and maintaining data integrity is critical, necessitating robust security measures.
2. Technological barriers: Limited access to technology or connectivity issues can exclude certain patient populations or introduce bias in the results.
3. Regulatory challenges: As DCTs are relatively new, regulatory bodies like the FDA are still developing guidelines to ensure compliance and safety.

Several companies have already adopted decentralized clinical trials with notable success. Science 37, a prominent DCT company, has collaborated with major pharmaceutical firms such as Novartis and Sanofi to conduct remote trials. In one particular case, their partnership with AOBiome led to the successful completion of a Phase 2b trial for a novel acne treatment, with 372 participants recruited in just three months.

Another example is Medable, which has developed a digital platform to streamline the DCT process. Their collaboration with PPD, a global contract research organization, has enabled more efficient and patient-centric trials across various therapeutic areas.

Several drug candidates have been tested or are being tested using DCTs. For instance, Pfizer's COVID-19 vaccine trials included a decentralized component, utilizing telemedicine and remote monitoring to manage a large participant pool.

RELATED: 9 Notable AI Companies in Clinical Research to Watch in 2023

Notable decentralized clinical trials companies:

Science 37 (https://www.science37.com/): 

Science 37 is a leader in decentralized clinical trials, offering an end-to-end solution through its NORA (Network Oriented Research Assistant) platform. The platform includes features such as telemedicine, eConsent, ePRO, and eCOA, enabling remote patient participation and data collection for various therapeutic areas.

Medable (https://www.medable.com/): 

Medable provides a flexible, modular platform for decentralized clinical trials, offering capabilities such as remote data collection, patient monitoring, and eConsent. Their platform aims to streamline the clinical trial process, increase patient engagement, and reduce study timelines.

THREAD Research (https://www.threadresearch.com/): 

THREAD specializes in decentralized clinical trials with a comprehensive platform that includes telehealth, eConsent, ePRO, and eCOA solutions. They focus on offering patient-centric experiences, which can improve recruitment and retention rates in clinical trials.

PRA Health Sciences (acquired by ICON) (https://www.prahs.com/): 

PRA Health Sciences (now ICON) offers a range of services for decentralized clinical trials, including remote patient monitoring, virtual site visits, and digital health tools. Their solutions are designed to provide flexibility and scalability, enabling sponsors to conduct trials efficiently and with improved patient outcomes.

Covance (https://www.covance.com/): 

As a part of Labcorp, Covance provides services for decentralized clinical trials that include patient recruitment, remote monitoring, and digital endpoints. They leverage their extensive clinical research experience to offer tailored solutions for various therapeutic areas and study types.

IQVIA (https://www.iqvia.com/): 

IQVIA is a global provider of advanced analytics, technology solutions, and contract research services. They offer a suite of solutions for decentralized clinical trials, including data management, virtual site visits, and patient engagement tools, designed to optimize trial efficiency and improve patient experiences.

Parexel (https://www.parexel.com/): 

Parexel is a global clinical research organization that offers a variety of services for decentralized clinical trials. Their solutions include eClinical platforms, digital health tools, and remote patient monitoring, which aim to enhance patient engagement and streamline the clinical trial process.

Oracle Health Sciences (https://www.oracle.com/industries/life-sciences/): 

Oracle offers a cloud-based platform for decentralized clinical trials, featuring data management, patient engagement, and remote monitoring solutions. Their integrated platform is designed to support innovative trial designs and improve trial efficiency.

Evidation Health (https://evidation.com/): 

Evidation Health focuses on generating real-world evidence from decentralized clinical trials by leveraging digital technology for data collection and analysis. Their platform enables the measurement of patient behavior and outcomes outside of traditional clinical settings, providing valuable insights for healthcare decision-making.

ObvioHealth (https://www.obviohealth.com/): 

ObvioHealth offers an end-to-end solution for decentralized clinical trials, including patient recruitment, remote data collection, and virtual site management. Their platform, ClaimIt, combines mobile technology, telemedicine, and data analytics to facilitate efficient and patient-centric clinical trials.

AI Technologies and Decentralized Clinical Trials

AI technologies are transforming various aspects of decentralized clinical trials, from patient recruitment to data analysis. Here are some key areas where AI is making a significant impact:

1. Patient recruitment and retention: AI algorithms can analyze vast amounts of patient data from electronic health records (EHRs), social media, and other sources to identify potential trial participants. This targeted approach improves recruitment rates and ensures a diverse and representative study population. Additionally, AI-driven chatbots and virtual assistants can improve patient engagement, leading to better retention rates throughout the trial.
2. Trial design optimization: AI can help optimize trial design by analyzing historical data and simulating different scenarios to predict outcomes. This can lead to more efficient study designs, reducing the duration and cost of trials, and enhancing the overall success rate.
3. Real-time data analysis: AI-driven analytics platforms can process and analyze large volumes of data collected during decentralized clinical trials, including data from wearables, mobile apps, and telemedicine consultations. This enables real-time monitoring, early detection of potential safety issues, and quicker decision-making.
4. Personalized interventions: AI technologies can analyze individual patient data to recommend tailored interventions, enhancing the patient experience and improving outcomes. In decentralized clinical trials, personalized medicine can lead to better treatment adherence and more accurate evaluations of drug candidates.
5. Regulatory compliance: AI can help decentralized clinical trials companies ensure compliance with FDA and other regulatory guidelines by automating data validation, monitoring data integrity, and identifying potential discrepancies in real-time.

RELATED: 8 Notable Companies Making Strides in Decentralized Clinical Trials

Among decentralized clinical trials companies, Deep 6 AI specializes in AI-driven patient recruitment for clinical trials, using natural language processing (NLP) and machine learning algorithms to identify suitable participants from EHRs and other data sources.

In summary, decentralized clinical trials are a prominent emerging trend in the pharmaceutical industry, offering numerous benefits for pharmaceutical professionals, biotech investors, clinicians, and healthcare professionals alike. As the FDA continues to support decentralized clinical trials and the market expands, it is essential for stakeholders to understand and adapt to this new era of clinical research.